Following the US Food & Drug Administration approval of Dr. Reddy’s ANDA for Lamotrigine XR tablets, the company has launched Lamotrigine Extended-Release tablets.
The Lamotrigine XR tablets are made available in 25mg, 50mg, 100mg, 200mg, and 300mg strengths as unit of use bottles of 30s.
For the most recent twelve months ending in April 2013, the sales of Lamictal XR brand and generic versions in the US areapproximately $300.5m MAT.
Containing a modified-release eroding formulation as the core, Lamictal XR (lamotrigine), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs.